Addex Therapeutics (ADXN.SW) Licensee Completes Enrollment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression
10/29/2013 9:30:12 AM
Addex Therapeutics (SIX: ADXN), a leading
company pioneering allosteric modulation-based drug discovery and development
announced today that Janssen Research & Development, LLC, on behalf of Janssen
Pharmaceuticals, Inc., has completed enrollment of 120 patients in a
multicenter, double-blind, Phase 2 study of ADX71149 in adults with major
depressive disorder who are also suffering anxiety symptoms.
Help employers find you! Check out all the jobs and post your resume.